Hospital-Based Contingency Management

Status Not yet recruiting

Clinical Trial Summary

This study aims to adapt an outpatient mobile app-based contingency management intervention to the hospital setting to understand how we can use contingency management to improve health outcomes in hospitalized patients with stimulant use disorders.

Clinical Trial Description

Contingency management (CM), an evidence-based strategy that utilizes a reward-based system as positive reinforcement, has been most robustly studied in the outpatient setting, but also has the potential to improve hospital care for patients with stimulant use disorder. The hospital is a challenging environment for people who use drugs. Conflicts with staff often result from in-hospital substance use, prolonged time off the unit, and missing medications, leading to negative health outcomes and re-admissions. By relying on positive rewards to encourage positive health behaviors, CM has the potential to improve staff-patient relationships, healthcare engagement, and reduce substance use in the hospital. Stimulant use disorder is especially difficult to address in the hospital due to a lack of medications that can support cravings and withdrawal symptoms. However, little is known about CM implementation in hospitals and the hospital setting may introduce unique challenges. The objective of this study is to adapt an outpatient mobile app-based CM intervention to the hospital setting to understand the feasibility and acceptability of a hospital-based CM intervention to improve health outcomes in hospitalized patients with substance use disorders. We'll achieve this objective through following specific aims: Aim 1: Identify adaptations needed to implement an evidence-based outpatient mobile-app based CM intervention to the hospital setting for hospitalized patients with substance use disorders. Aim 2: Determine the feasibility, including facilitators and barriers, of implementing a mobile app-based CM intervention in the hospital setting. Aim 3: Assess the acceptability of a mobile app-based hospital-based CM intervention to patients and staff. ;

Study Design

Related Conditions & MeSH terms

Amphetamine-Related Disorders

Clinical Trial Details

NCT number	NCT05515757
Study type	Interventional
Source	Oregon Health and Science University
Contact	Linda Peng, MD
Phone	8054059761
Email	pengli@ohsu.edu
Status	Not yet recruiting
Phase	N/A
Start date	August 22, 2022
Completion date	August 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02232789` - Abuse Liability and Human Pharmacology of Mephedrone	Phase 1
Completed	`NCT01449565` - Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)	Phase 2
Completed	`NCT00247572` - Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories	Phase 2
Active, not recruiting	`NCT00100074` - To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1	Phase 1
Active, not recruiting	`NCT00033072` - Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1	Phase 1
Recruiting	`NCT06145698` - Treatment Effect of Cross-frequency Transcranial Alternating Current Stimulation on the MUD	N/A
Completed	`NCT00990067` - Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)	Phase 1
Completed	`NCT02797990` - Conflict Between Maternal Autonomy and Child Health in Substance-use	N/A
Recruiting	`NCT01899313` - A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence	N/A
Active, not recruiting	`NCT00265278` - Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1	Phase 1
Active, not recruiting	`NCT00000350` - Effects of Stimulant Dependence on Human Striatal Dopamine System - 15	Phase 1
Active, not recruiting	`NCT00089440` - Assessment of Interactions Between Methamphetamine and Aripiprazole - 1	Phase 1
Active, not recruiting	`NCT00040040` - Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1	Phase 1
Completed	`NCT00040053` - Ondansetron for the Treatment of Methamphetamine Dependence - 1	Phase 2
Completed	`NCT00895804` - Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)	Phase 1
Recruiting	`NCT03902405` - Computerized Exercise to Alter Stimulant Approach Responses	N/A
Recruiting	`NCT04982796` - Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder	Phase 1/Phase 2
Completed	`NCT01386177` - Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)	Phase 1
Completed	`NCT01136278` - Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA)	Phase 1
Completed	`NCT00069251` - Bupropion for the Treatment of Methamphetamine Dependence - 1	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.